November 10, 2018New England Journal of Medicine
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Why the study?
Does icosapent ethyl 2 g twice daily reduce ischemic events in patients with elevated triglyceride levels despite the use of statins?
Population
Patients with elevated triglyceride levels despite the use of statins
Comparison
Icosapent ethyl 2 g twice daily vs Placebo
Design
RCT
Authors
Discussion
Loading...
Member takes
Implication
Supports icosapent ethyl addition in statin-treated patients with elevated triglycerides; confirms ischemic event reduction in this population.
Key Points
- The aim is to evaluate the effectiveness of icosapent ethyl in reducing cardiovascular events in patients with high triglycerides.
- Randomized trial comparing icosapent ethyl (2 g, twice daily) to placebo
- Participants included patients with elevated triglycerides despite statin therapy
- Clinical trial registered under NCT01492361.
- Icosapent ethyl reduced the risk of ischemic events compared to placebo
- Significantly lower rates of cardiovascular death observed in the treatment group.
Structured PICO
Does icosapent ethyl 2 g twice daily reduce ischemic events in patients with elevated triglyceride levels despite the use of statins?
P
Population
Patients with elevated triglyceride levels despite the use of statins
I
Intervention
Icosapent ethyl 2 g twice daily
C
Comparator
Placebo
O
Outcome
Ischemic events, including cardiovascular deathhard clinical
Icosapent ethyl significantly reduces the risk of ischemic events in statin-treated patients with elevated triglycerides.
Cite This Study
Bhatt et al. (2018) studied this question.